ArticleInfectious diseases & immunity2025
Characteristics and risk factors of acquired drug resistance among people living with HIV: A retrospective study in Guangzhou, China (2018-2023).
Article in Infectious diseases & immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Erratum: Characteristics and risk factors of acquired drug resistance among people living with HIV: A retrospective study in Guangzhou, China (2018-2023): Erratum.Infectious diseases & immunity · 2026Article
- Prevalence and transmission of pretreatment drug resistance and acquired drug resistance among people living with HIV-1 in Chongqing, China, 2014-2024.Frontiers in public health · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acquired drug resistance (ADR) in people living with HIV (PLWH) reduces treatment efficacy, restricts drug options, and increases the risk of human immunodeficiency virus (HIV) transmission. The resistance characteristics and associated risk factors of PLWH suffering from virological failure (VF) in Guangdong remain unclear, thus highlighting the need for further research in this area. This retrospective study examines the prevalence, resistance characteristics, and contributing factors of ADR among PLWH who experienced VF in Guangzhou, China, between 2018 and 2023. Methods: Blood samples, epidemiological and demographic data were collected from PLWH with VF at Guangzhou Eight People's Hospital in Guangzhou, China, between January 1, 2018 and December 1, 2023. ADR was analyzed through HIV Results: A total of 1592 patients experienced VF during the study period, with 959 having protease/reverse transcriptase sequences and 479 having integrase sequences. DRMs were identified in 60.2% (577/959) of the patients, with an overall ADR prevalence of 46.1% (442/959). The resistance rates for specific drug classes were as follows: nucleotide reverse transcriptase inhibitors (NRTIs) at 33.3% (319/959), non-nucleoside reverse transcriptase inhibitors (NNRTIs) at 36.8% (353/959), protease inhibitors at 3.3% (32/959), and integrase strand transfer inhibitors (INSTIs) at 1.5% (7/479). The multivariable logistic regression analysis revealed several factors linked to a higher risk of ADR, including World Health Organization clinical stages III and IV, baseline CD4 Conclusion: The prevalence of ADR in Guangzhou was primarily driven by NNRTI resistance. The choice and use of treatment regimens are closely linked to ADR occurrence, and minimizing unnecessary regimen changes may help significantly lower ADR risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.